Editor Although less often in the headlines during recent years, quietly murderous HIV has gone about its dark business worldwide with terrible efficiency. AIDS has killed 20 million people since beginning that sinister march across the earth, and another 40 million are infected with the virus. Most of the newly infected (an estimated 70 percent) are in Africa, where 2.2 million died last year, but in the U.S., where new AIDS cases had been dropping until 1998, the disease has leveled out at

Company* (Country; Symbol) Product Description Indication Status (Date) AUTOIMMUNE Biogen Inc. (BGEN) Amevive Alefacept; novel immunomodulatory agent that selectively targets the CD45RO+ subset of T cells Chronic plaque psoriasis FDA issued a complete response letter and requested additional information and clarification, but no new trials are needed (6/14) CANCER Corixa Corp. (CRXA) Bexxar Tositumomab and iodine-131 tositumomab; an investigational radioimmunotherapy

Company* (Country; Symbol) Product Description Indication Status (Date) AUTOIMMUNE Isis Pharmaceuticals Inc. (ISIS) Alicaforsen (ISIS 2302) Antisense inhibitor of intercellular adhesion molecule-1 Crohn's disease Company initiated a second Phase III trial with 150 patients at 35 sites in Europe (6/25) CANCER Advanced Viral Research Corp. (OTC BB:ADVR) Product R A nontoxic peptide- nucleic acid-type immunomodulator that appears to stimulate the proinflammatory responses

Company* (Country; Symbol) Product Description Indication Status (Date) AUTOIMMUNE Biogen Inc. (BGEN) Avonex (FDA- approved) Interferon beta-1a Multiple sclerosis Clinical data showed early treatment with Avonex can reduce the rate at which individuals at particularly high risk for the disease develop clinically definite multiple sclerosis (6/26) Cambridge Anti- body Technology Group plc (UK; CATG; LSE:CAT) D2E7 Fully human antibody; adalimumab Rheumatoid arthritis

Money Raised Year To Date

Editor During the 1960s, labels of any kind were abhorred by many for the way they so fixedly identified objects and people, limiting them to a static condition that idealistic New Agers whose cultural influence spread far in that era could hardly abide. The world in those halcyon days was seen as free flowing, and to harden it by applying nouns was derided as almost brutal. Anti-scientific as the movement against everyday "labeling" was, it took a long time to subside. And, after the

I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $311.05M Company Location Date Amt. (M) Details Biopsytec Holding AG Berlin 6/28 €5 (US$4.9) Biopsytec raised more than US$4.9M in a second round of financing led by SAM Sustainability Private Equity LP; other investors were Deutsche Venture Capital and Industrie Management Holdings Cellectis SA Paris 6/25 €16 (US$15.7) Cellectis completed a second round of financing, raising €16M (US$15.7M); investors included BankInvest

Total: $63.26M Company (Symbol)# Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (M) Investors; Placement Agents; Details (Date)@ Advanced Biotherapy Inc. (OTC BB:ADVB) Private placement of subordinated convertible notes N/A $3.7 Advanced Biotherapy raised about $3.7M through a private placement of notes (6/17) Bavarian Nordic A/S (Denmark; CSE:BAVA) Private placement of common stock 0.96S DKK67 (US$8.8) Bavarian Nordic raised US$8.8M when

I. COMMENCED TRADING IN JUNE Company (Symbol)# Date Filed Date Comm. Shares/ Units (M) Price Shares Out (M)% Lead, Other Underwriters Gross (M) Post- Offering Market Cap (M)@ INITIAL OFFERINGS BioDelivery Sciences Inc. (BDSIU)1 11/2002 6/27 2U $5.25 7 Kashner Davidson Securities; Roan Meyers Assoc.; Investors Capital; Sterling Financial Investment; Schneider Securities $10.5 N/A YM BioSciences Inc. (Canada; AIM:YMB; TSE:YM_PB)2 4/24/02 6/12/02 3.75S C$4 16

Money Raised Year To Date - July 8, 2002

Editor You don't need much, but you better have some or else. The subject is enzymes, replacement therapy for which has been in the forefront in June, with big player Genzyme General Corp. and partner BioMarin Pharmaceuticals Inc. making headlines (good news), as well as competitor Oxford GlycoSciences plc (bad news). Genzyme, of course, is known for its already-marketed treatments for Gaucher's disease, Cerezyme (recombinant glucocerebrosidase) and Ceredase, the natural version of the enzyme

An item on Molichem Medicines Inc.'s Moli1901 product for cystic fibrosis in a chart in the June 17, 2002, issue of BioWorld Financial Watch should have described it is a muco-active polypeptide. Editor's Note: The correction has been made in BioWorld Online.